PBDA Stock Chart & Stats
€2.20
€0.00(0.00%)
At close: 4:00 PM EDT
€2.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.36 - €2.66
Previous CloseN/A
Volume0.00
Average Volume (3M)51.00
Market Cap
€187.51M
Enterprise Value€160.20M
Total Cash (Recent Filing)€27.42M
Total Debt (Recent Filing)€9.21M
Price to Earnings (P/E)11.2
Beta1.11
Next Earnings
Nov 16, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding80,571,640
10 Day Avg. Volume0
30 Day Avg. Volume51
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.71Price Target Upside386.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.16
Revenue Forecast (FY)€70.09M
Bulls Say, Bears Say
Bulls Say
Improved ProfitabilityThe return to positive earnings and strong operating margins indicates that Protalix can currently convert product revenue into meaningful profit. If commercial sales remain durable, this improved earnings base should support internal funding, investment in the pipeline, and greater resilience over the next several quarters.
Strong Balance SheetA debt-free balance sheet and substantial liquidity give Protalix flexibility to fund operations and advance clinical programs without immediate financing pressure. This reduces interest burden and preserves strategic options while the company develops commercial products and evaluates future pipeline needs.
Elfabrio Commercial And Regulatory ExpansionAdditional geographic approval and a less frequent dosing option can broaden Elfabrio’s commercial reach and improve its fit for patients and prescribers. Continued partner-led adoption could strengthen recurring product economics and support Protalix’s position in the Fabry disease market.
Bears Say
Partner Concentration And Sales LumpinessDependence on Chiesi purchasing patterns means reported revenue may not track underlying demand smoothly, making earnings and cash generation harder to forecast. Uneven shipments can also obscure the durability of commercial growth and increase reliance on partner execution over the next several quarters.
Reliance On A Non-recurring MilestoneThe milestone materially boosted first-half revenue but is not expected to recur in the same way, reducing comparability with future periods. Unless recurring Elfabrio sales replace that contribution, reported growth and profitability could moderate after the milestone-supported base rolls off.
PRX-115 Clinical UncertaintyThe observed immunogenicity and unresolved regimen choice could complicate PRX-115’s development path, affecting trial design, timing, and eventual market positioning. These issues create execution risk for a pipeline asset that may otherwise provide an important future growth opportunity.
Protalix News
PBDA FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was €1.36 and its highest was €2.66 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is €187.51M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 30 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Aug 12, 2026. The company reported €0.045 earnings per share for the quarter, beating the consensus estimate of -€0.009 by €0.054.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is -0.02.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,571,640 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of €0.045 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went up 7.637%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in DE:PBDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€10.71 (386.75% Upside)
€10.71 (386.75% Upside)
Blogger Sentiment
Bearish
DE:PBDA Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.43%
12-Months-Change
Fundamentals
Return on Equity
31.61%
Trailing 12-Months
Asset Growth
40.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
PBDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented several strong operational and financial positives — double-digit quarterly revenue growth, a >100% year-to-date revenue increase, meaningful Q2 net income, strong Elfabrio commercial momentum with regulatory and patent tailwinds, a solid cash position and advancing pipeline (PRX-115 with topline expected H2 2027). Offsetting risks include quarter-to-quarter revenue lumpiness and partner concentration (Chiesi), a reliance on a one-time $25M milestone in H1, increased cost of revenues and taxes, and clinical uncertainties around immunogenicity and regimen selection for PRX-115. Overall, the positives — particularly the robust revenue growth, improved profitability and cash position — outweigh the noted risks, though sustainability and immunogenicity remain items to monitor.View all DE:PBDA earnings summariesPBDA Stock 12 Month Forecast
Average Price Target
€10.71
▲(386.75% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
―
Innate Pharma
―